Contineum Therapeutics, Inc. reported Q4 2025 financial results with net loss of $15.2 million and cash of $262.9 million as of December 31, 2025, sufficient into mid-2029. The company amended its Sales Agreement with Leerink Partners to increase the at-the-market offering capacity to $100 million and initiated dosing in the PROPEL-IPF Phase 2 trial for PIPE-791 in IPF patients.
Key takeaways
Issued press release on March 5, 2026, announcing Q4 2025 financial results with net loss $15,156 thousand vs $14,565 thousand prior year
Cash, cash equivalents and marketable securities $262.9 million as of December 31, 2025
Amended Sales Agreement dated May 14, 2025, with Leerink Partners on March 5, 2026, to offer up to $100 million of Class A common stock
Filed ATM Prospectus Supplement on March 5, 2026, superseding prior supplement; no sales until after March 11, 2026 lock-up
Initiated patient dosing in PROPEL-IPF global Phase 2 trial of PIPE-791 for IPF with 324 patients
Topline data from PIPE-791 Phase 1b chronic pain trial expected Q2 2026